Cargando…
Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus
BACKGROUND: Sitagliptin is a highly selective dipeptidyl peptide-4 (DPP-4) inhibitor that increases blood levels of active glucagon-like peptide (GLP)-1 and glucose-dependent insulinotrophic polypeptide (GIP), resulting in increased insulin secretion. While studies conducted in other countries have...
Autores principales: | Kim, Soon Ae, Shim, Woo Ho, Lee, Eun Hae, Lee, Young Mi, Beom, Sun Hee, Kim, Eun Sook, Yoo, Jeong Seon, Nam, Ji Sun, Cho, Min Ho, Park, Jong Suk, Ahn, Chul Woo, Kim, Kyung Rae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Diabetes Association
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122893/ https://www.ncbi.nlm.nih.gov/pubmed/21738898 http://dx.doi.org/10.4093/dmj.2011.35.2.159 |
Ejemplares similares
-
Response: Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus (Diabetes Metab J 2011;35:159-65)
por: Kim, Soon Ae, et al.
Publicado: (2011) -
Visceral Fat Thickness Predicts Fatty Liver in Koreans with Type 2 Diabetes Mellitus
por: Kim, Hai Jin, et al.
Publicado: (2008) -
Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus
por: Park, Jong Suk, et al.
Publicado: (2011) -
Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus
por: Yang, Hae Kyung, et al.
Publicado: (2015) -
Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double‐blind, non‐inferiority trial
por: Kim, Yonghyun, et al.
Publicado: (2018)